Mesenchymal stromal cells to protect kidney after traumatic hemorrhagic shock

Background & AimHaemorrhagic shock (HS) refers to the inadequate perfusion of tissues due to the imbalance between systemic oxygen delivery and consumption. Blunt or penetrating trauma is the most common cause of HS. The development of multiorgan failure after severe trauma is one of the leading...

Full description

Saved in:
Bibliographic Details
Published inCytotherapy (Oxford, England) Vol. 21; no. 5; pp. S51 - S52
Main Authors Peltzer, J, Aussel, C, Baudry, N, Allain, E, Grosbot, M, Vicaut, E, Banzet, S
Format Journal Article
LanguageEnglish
Published Elsevier Inc 01.05.2019
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background & AimHaemorrhagic shock (HS) refers to the inadequate perfusion of tissues due to the imbalance between systemic oxygen delivery and consumption. Blunt or penetrating trauma is the most common cause of HS. The development of multiorgan failure after severe trauma is one of the leading causes of morbidity and late mortality. Among critical organs, the Acute Kidney Injury (AKI) affects up to 50% of the patients and no etiologic treatment is available.Mesenchymal Stromal Cells (MSC) are multipotent cells found in a large number of adult tissues and used in clinical practice as a therapeutic agent for immunomodulation and tissue repair. Many studies have highlighted their immunomodulatory, anti-apoptotic/anti-oxidative stress, pro-angiogenic effect, stimulation of endogenous regenerative process or anti-fibrotic effect by direct contact or by secreting bioactive molecules. Our objective was to evaluate and optimize an early MSC therapy after traumatic hemorrhagic shock (THS) inducing an AKI.Methods, Results & ConclusionWe have developed in vivo THS model and validated functional assays on cultures of immune and renal human cells. In vivo, rats were subjected to 1h of HS at a Mean Arterial Pressure of 30mmHg, associated with administration of 1ml plasma from THS animals. Biological and histological analyses are currently performed on D2, D7 and D21. In vitro, a cellular model of renal injury was developed by adding a "shock cocktail" (SC) containing inflammatory cytokines, HMGB1, histones and H 2O 2. Several criteria have been studied: Membrane polarization of the mitochondria by the JC1 dye, MitoSOX and CellROX probes to evaluate the mitochondrial and cytoplasmic oxidation state. Aggression of renal cells induced a decrease in the mitochondrial membrane polarization. The CellROX probe also showed an increase in cytoplasmic oxidative stress. We also developed a model of inflammation using THP1 cell line treated with SC. The SC induced an increase in TNFα secretion by THP1. Our main preliminary results indicated that MSCs improved the viability of renal cells, partially restored their mitochondrial membrane potential and decreased their cytoplasmic oxidative stress. In addition, they can exert an anti-inflammatory effect by inhibited the secretion of TNFα by THP1 and increased their secretion of the anti-inflammatory cytokine IL1RA. Finally, the pre-clinical model mimicking a polytrauma could be a formidable tool to evaluate the benefit of MSC therapy, away from shock.
AbstractList Haemorrhagic shock (HS) refers to the inadequate perfusion of tissues due to the imbalance between systemic oxygen delivery and consumption. Blunt or penetrating trauma is the most common cause of HS. The development of multiorgan failure after severe trauma is one of the leading causes of morbidity and late mortality. Among critical organs, the Acute Kidney Injury (AKI) affects up to 50% of the patients and no etiologic treatment is available. Mesenchymal Stromal Cells (MSC) are multipotent cells found in a large number of adult tissues and used in clinical practice as a therapeutic agent for immunomodulation and tissue repair. Many studies have highlighted their immunomodulatory, anti-apoptotic/anti-oxidative stress, pro-angiogenic effect, stimulation of endogenous regenerative process or anti-fibrotic effect by direct contact or by secreting bioactive molecules. Our objective was to evaluate and optimize an early MSC therapy after traumatic hemorrhagic shock (THS) inducing an AKI. We have developed in vivo THS model and validated functional assays on cultures of immune and renal human cells. In vivo, rats were subjected to 1h of HS at a Mean Arterial Pressure of 30mmHg, associated with administration of 1ml plasma from THS animals. Biological and histological analyses are currently performed on D2, D7 and D21. In vitro, a cellular model of renal injury was developed by adding a "shock cocktail" (SC) containing inflammatory cytokines, HMGB1, histones and H2O2. Several criteria have been studied: Membrane polarization of the mitochondria by the JC1 dye, MitoSOX and CellROX probes to evaluate the mitochondrial and cytoplasmic oxidation state. Aggression of renal cells induced a decrease in the mitochondrial membrane polarization. The CellROX probe also showed an increase in cytoplasmic oxidative stress. We also developed a model of inflammation using THP1 cell line treated with SC. The SC induced an increase in TNFα secretion by THP1. Our main preliminary results indicated that MSCs improved the viability of renal cells, partially restored their mitochondrial membrane potential and decreased their cytoplasmic oxidative stress. In addition, they can exert an anti-inflammatory effect by inhibited the secretion of TNFα by THP1 and increased their secretion of the anti-inflammatory cytokine IL1RA. Finally, the pre-clinical model mimicking a polytrauma could be a formidable tool to evaluate the benefit of MSC therapy, away from shock.
Background & AimHaemorrhagic shock (HS) refers to the inadequate perfusion of tissues due to the imbalance between systemic oxygen delivery and consumption. Blunt or penetrating trauma is the most common cause of HS. The development of multiorgan failure after severe trauma is one of the leading causes of morbidity and late mortality. Among critical organs, the Acute Kidney Injury (AKI) affects up to 50% of the patients and no etiologic treatment is available.Mesenchymal Stromal Cells (MSC) are multipotent cells found in a large number of adult tissues and used in clinical practice as a therapeutic agent for immunomodulation and tissue repair. Many studies have highlighted their immunomodulatory, anti-apoptotic/anti-oxidative stress, pro-angiogenic effect, stimulation of endogenous regenerative process or anti-fibrotic effect by direct contact or by secreting bioactive molecules. Our objective was to evaluate and optimize an early MSC therapy after traumatic hemorrhagic shock (THS) inducing an AKI.Methods, Results & ConclusionWe have developed in vivo THS model and validated functional assays on cultures of immune and renal human cells. In vivo, rats were subjected to 1h of HS at a Mean Arterial Pressure of 30mmHg, associated with administration of 1ml plasma from THS animals. Biological and histological analyses are currently performed on D2, D7 and D21. In vitro, a cellular model of renal injury was developed by adding a "shock cocktail" (SC) containing inflammatory cytokines, HMGB1, histones and H 2O 2. Several criteria have been studied: Membrane polarization of the mitochondria by the JC1 dye, MitoSOX and CellROX probes to evaluate the mitochondrial and cytoplasmic oxidation state. Aggression of renal cells induced a decrease in the mitochondrial membrane polarization. The CellROX probe also showed an increase in cytoplasmic oxidative stress. We also developed a model of inflammation using THP1 cell line treated with SC. The SC induced an increase in TNFα secretion by THP1. Our main preliminary results indicated that MSCs improved the viability of renal cells, partially restored their mitochondrial membrane potential and decreased their cytoplasmic oxidative stress. In addition, they can exert an anti-inflammatory effect by inhibited the secretion of TNFα by THP1 and increased their secretion of the anti-inflammatory cytokine IL1RA. Finally, the pre-clinical model mimicking a polytrauma could be a formidable tool to evaluate the benefit of MSC therapy, away from shock.
Author Aussel, C
Grosbot, M
Banzet, S
Baudry, N
Peltzer, J
Allain, E
Vicaut, E
Author_xml – sequence: 1
  fullname: Peltzer, J
– sequence: 2
  fullname: Aussel, C
– sequence: 3
  fullname: Baudry, N
– sequence: 4
  fullname: Allain, E
– sequence: 5
  fullname: Grosbot, M
– sequence: 6
  fullname: Vicaut, E
– sequence: 7
  fullname: Banzet, S
BookMark eNp9kM1Kw0AUhQepYKu-gKu8QOL8JJMERJDiH7S4UNfD5ObGTJpmysxUyNubUFcuXJ2zOZf7fSuyGOyAhNwwmjDK5G2XdDCGhFNWJlQkKZNnZMnSPI95JuVi7jKLBU_LC7LyvqOU06LIlmS7RY8DtONe95EPzs4J2Pc-CjY6OBsQQrQz9YBjpJuALgpOH_c6GIha3FvnWv01dd9a2F2R80b3Hq9_85J8Pj1-rF_izdvz6_phEwPLmIxRCuA0l5KXIEpBGaNZVQjNK0qBYdpURV3RptG1RtEIwLqGoshFUVWQ57UUl4Sf7oKz3jts1MGZvXajYlTNQlSnZiFqFqKoUJOQaXR3GuH02bdBpzyYiR1r4yZIVVvz__z-zxx6MxjQ_Q5H9J09umFiVkx5rqh6n43PwtkEmMk8Ez_J5oI2
ContentType Journal Article
Copyright 2019
Copyright_xml – notice: 2019
DBID AAYXX
CITATION
DOI 10.1016/j.jcyt.2019.03.416
DatabaseName CrossRef
DatabaseTitle CrossRef
DatabaseTitleList

DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1477-2566
EndPage S52
ExternalDocumentID 10_1016_j_jcyt_2019_03_416
S1465324919305675
1_s2_0_S1465324919305675
GroupedDBID ---
--M
.1-
.FO
.~1
1P~
1~.
29F
36B
4.4
457
4G.
53G
5GY
5VS
7-5
8P~
AAAJQ
AACTN
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAOAW
AAXKI
AAXUO
ABDBF
ABGSF
ABJNI
ABMAC
ABMZM
ABUDA
ABXDB
ACDAQ
ACGEJ
ACGFS
ACRLP
ADBBV
ADCVX
ADEZE
ADXPE
AEBSH
AEHWI
AEKER
AENEX
AEVXI
AFCTW
AFJKZ
AFKVX
AFKWA
AFRHN
AFTJW
AFXIZ
AGEKW
AGHFR
AGRDE
AGUBO
AGYEJ
AIEXJ
AIKHN
AITUG
AJOXV
AJRQY
AJUYK
AJWEG
AKRWK
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
ANZVX
ASPBG
AVWKF
AWYRJ
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
CAG
CJTIS
COF
CS3
DU5
EAP
EBC
EBS
EFJIC
EJD
EMB
EMK
EMOBN
ESX
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
GBLVA
H13
HVGLF
HZ~
KOM
LUGTX
M44
MO0
O-L
O9.
OAUVE
OK~
P-8
P-9
P2P
PC.
Q38
R2-
ROL
SDF
SPCBC
SSH
SSI
SSU
SSZ
SV3
T5K
TDBHL
TFW
Z5R
~G-
AAIAV
ABLVK
ABYKQ
AJBFU
DOVZS
EFLBG
LCYCR
AAYXX
CITATION
ID FETCH-LOGICAL-c1516-e63c2076629c39301105b83a2b00c1e4fb8db0ffadae3f3ceddc88738bbc77d63
IEDL.DBID AIKHN
ISSN 1465-3249
IngestDate Fri Dec 06 03:34:15 EST 2024
Fri Feb 23 02:16:03 EST 2024
Tue Oct 15 22:56:13 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 5
Language English
License https://www.elsevier.com/tdm/userlicense/1.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c1516-e63c2076629c39301105b83a2b00c1e4fb8db0ffadae3f3ceddc88738bbc77d63
ParticipantIDs crossref_primary_10_1016_j_jcyt_2019_03_416
elsevier_sciencedirect_doi_10_1016_j_jcyt_2019_03_416
elsevier_clinicalkeyesjournals_1_s2_0_S1465324919305675
PublicationCentury 2000
PublicationDate May 2019
PublicationDateYYYYMMDD 2019-05-01
PublicationDate_xml – month: 05
  year: 2019
  text: May 2019
PublicationDecade 2010
PublicationTitle Cytotherapy (Oxford, England)
PublicationYear 2019
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
SSID ssj0020885
Score 2.2614846
Snippet Background & AimHaemorrhagic shock (HS) refers to the inadequate perfusion of tissues due to the imbalance between systemic oxygen delivery and consumption....
Haemorrhagic shock (HS) refers to the inadequate perfusion of tissues due to the imbalance between systemic oxygen delivery and consumption. Blunt or...
SourceID crossref
elsevier
SourceType Aggregation Database
Publisher
StartPage S51
SubjectTerms Advanced Basic Science
Other
Title Mesenchymal stromal cells to protect kidney after traumatic hemorrhagic shock
URI https://www.clinicalkey.es/playcontent/1-s2.0-S1465324919305675
https://dx.doi.org/10.1016/j.jcyt.2019.03.416
Volume 21
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT4NAEJ74uHgxPmN9ZQ_Gi2JZFthybIymato0URNvG3bZTauxbQo9cPG3OwuLj2g8eCKQLJAP5vt2YeYbgBM_UtqozHimoxIP9TbwZKaUJ2liOEfN1lXTvv4g7j2Gt0_R0xJcNrUwNq3ScX_N6RVbuyNth2Z7Nh6376m1BsPVA05BUMV5tAyrKEf2X-1q9-auN_hYd2EgRXWRUeTZAa52pk7zelalTamklddpaNue_6ZPXzTnegPW3WSRdOv72YQlPdmC02HtNl2ek4fP4qn8nJyS4acPdbkN_b6tLFKj8hXPkRfzqd3aD_U5KabEGTSQl3E20SWpeoWTYp4uKg9XMrIZuPNRisRI8hGS5g48Xl89XPY81z3BU6jisadjpgKfx3GQKJbYOPYj2WFpgIGmqA6N7GTSNybNUs0MQ7wzhYzDOlIqzrOY7cLKZDrRe0BoYKjhsS-ZkWGqgpSyMMWVZaZDmSRcteCswUzMapMM0WSPPQuLsLAIC58JRLgFvIFVNOWfSFg6d9GTCyryQPjixxNuQfQx8ttLIpD__7ji_j_HHcCa3avzGw9hpZgv9BHOQQp5DMsXb_TYvWnvu0vdlQ
link.rule.ids 314,780,784,4502,24116,27924,27925,45585,45679
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV07T8MwED5BGWBBPEV5ekAsNDSJk7gZUUVVoEVIFKmbFTu22iJa1IQhC7-dcx4tCMTAFCmJk-iL77uz9d0dwLntS6VlrC3dkqGF_ta1RCylJZxQM4Y-W-VN-_oPQffZuxv6wxVoV7kwRlZZcn_B6Tlbl2eaJZrNt_G4-eSY0mC4esAQBL0481dhzfMx-sVJffWx0Hm4aEZ-kWLkW-b2MnOmEHlNZGYElU5e6dQzTc9_805fPE5nCzbLUJFcF1-zDStqugMXj0Wt6axBBsvUqaRBLsjjsgp1tgv9vskrkqPsFZ-RpPOZOZpt-oSkM1KWZyAv43iqMpJ3CifpPHrPK7iSkdHfzkcR0iJJRkiZe_DcuRm0u1bZO8GS6MMDSwVUujYLAjeUNDRWbPuiRSMXzUw6ytOiFQtb6yiOFNUU0Y4l8g1tCSEZiwO6D7XpbKoOgDiudjQLbEG18CLpRg71IlxXxsoTYchkHS4rzPhbUSKDV9qxCTcIc4MwtylHhOvAKlh5lfyJdKWS0nYS7vDE5Tb_8X_r4C9GfpsiHNn_jzce_nPcGax3B_0e790-3B_BhrlSKB2PoZbO39UJRiOpOM1n2ye9B95u
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Mesenchymal+stromal+cells+to+protect+kidney+after+traumatic+hemorrhagic+shock&rft.jtitle=Cytotherapy+%28Oxford%2C+England%29&rft.au=Peltzer%2C+J&rft.au=Aussel%2C+C&rft.au=Baudry%2C+N&rft.au=Allain%2C+E&rft.date=2019-05-01&rft.issn=1465-3249&rft.volume=21&rft.issue=5&rft.spage=S51&rft.epage=S52&rft_id=info:doi/10.1016%2Fj.jcyt.2019.03.416&rft.externalDBID=ECK1-s2.0-S1465324919305675&rft.externalDocID=1_s2_0_S1465324919305675
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F14653249%2FS1465324919X00067%2Fcov150h.gif